Chronic Kidney Disease

Opinions on the effectiveness and usefulness of telehealth services varied among clinicians and older patients with chronic kidney disease (CKD), suggesting that new measures and training programs should be put in place to mitigate disparities and accessibility issues.

Patients with chronic kidney disease (CKD) and elevated levels of parathyroid hormone who are treated with active vitamin D therapy experienced significantly higher risks of hypercalcemia, investigators concluded in a meta-analysis.

A tool utilizing 5 predictors was found to be reliable at identifying patients at a high risk of cardiovascular disease who were also at risk of developing chronic kidney disease (CKD), potentially allowing providers to implement prevention strategies sooner than ever before.

Improving clinical care is only one element of the 360-degree, holistic treatment that is necessary to achieve patient equity, not equality, in patients with chronic kidney disease. Biology, lifestyle, and socioeconomic status are 3 areas in which inequities often have a particularly negative impact on a carefully constructed care plan.

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association (ADA), describes the ADA's efforts to elevate the conversation about the impact of diabetes on kidney disease.

Investigators found that increased heart rate correlated with a decline in the ability for the kidneys to function at 48 weeks after a patient receives a kidney transplant, according to results presented at the 2021 American Heart Association Scientific Sessions.

On this episode of Managed Care Cast, we speak with Abi Sundaramoorthy, MD, MBA, executive vice president of clinical enterprise at Somatus, on fragmented care in chronic kidney disease, its disproportionate impact on minority communities, and the potential of value-based arrangements to address disparities and promote preventive, effective care.

Hospitalization for an acute kidney injury (AKI) event was identified as a risk factor for several adverse events after hospital discharge, including hospital readmission and mortality, according to findings presented at Kidney Week 2021.

Conference abstracts explored the relationship between serum phosphate levels on mortality in patients with chronic kidney disease (CKD) and cost burdens for employers as patients transition to end-stage renal disease.

Daprodustat had no increased cardiovascular risk, compared with erythropoiesis stimulating agents (ESAs), in treating anemia in patients with chronic kidney disease (CKD) who were on dialysis and not on dialysis.

To help close health equity gaps, CMS finalized a rule that will update payment rates and improve incentives for providers to encourage them to increase access to home dialysis and kidney transplants for low-income patients with end-stage renal disease.

A brief overview of the STEP trial and results from intensive blood-pressure control in elderly patients with hypertension.

Insight on the unmet needs in management of heart failure, specifically regarding access to therapeutic agents that can alter the course of disease.

Rajiv Agarwal, MD, MS, reflects on pooled data from the EMPEROR-Reduced and EMPEROR-Preserved trials.

An overview of and results from the EMPEROR-Preserved trial, which tested the effects of empagliflozin in patients with HFpEF.

Considerations for the benefit shown in combining finerenone with SGLT2 inhibitors in patients with type 2 diabetes and CKD.

Rajiv Agarwal, MD, MS, considers the practical implications of the FIDELITY pooled analysis and how it may impact clinical practice.

A review of results from the FIDELITY pooled analysis analyzing finerenone’s impact on cardiorenal morbidity and mortality in patients with type 2 diabetes and CKD.

An overview of the FIDELITY analysis, which pooled data from the FIGARO-DKD and FIDELIO-DKD trials in patients with type 2 diabetes and CKD.

Long-awaited reports released Thursday call for eliminating race in estimated glomerular filtration rate equations and point to alternatives in an effort to eliminate disparities in chronic kidney disease.

Rajiv Agarwal, MD, MS, shares expert insight on the results of FIGARO-DKD with respect to the trial’s primary and secondary end points.

An overview of the FIGARO-DKD trial, which evaluated cardiovascular and renal outcomes in patients with type 2 diabetes and CKD treated with finerenone.

This new analysis aimed to pinpoint more rigorous predictors of mortality, and it was able to identify “excellent” but not “outstanding” ones, according to the investigators.